Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

April 18, 2026

Study Completion Date

October 18, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Nanobody-based biepitope BCMA-targeting CAR-T cells

Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.

Trial Locations (1)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

collaborator

Huazhong University of Science and Technology Union Shenzhen Hospital

UNKNOWN

collaborator

The Seventh Affiliated Hospital of Sun Yat-sen University

OTHER

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER